<DOC>
	<DOCNO>NCT00294047</DOCNO>
	<brief_summary>This multicentre study woman plan receive either Human Papillomavirus Vaccine ( HPV ) vaccine control . Under Protocol Amendment 3 , study participation last approximately 48 month involve total eleven schedule visit . Under Protocol Amendment 4 , study participation last 84 month involve maximum seventeen schedule visit .</brief_summary>
	<brief_title>Study Evaluate Efficacy Human Papillomavirus Vaccine Healthy Adult Women 26 Years Age Older</brief_title>
	<detailed_description>The Protocol Posting update due protocol amendment 5 order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Inclusion criterion : A woman investigator believe comply requirement protocol . A woman least 26 year age time first vaccination . Written inform consent obtain subject prior enrolment . Free obvious health problem establish medical history clinical examination enter study . Subject must intact cervix . Subject must negative urine pregnancy test . This test applicable woman nonchildbearing potential . Subject must nonchildbearing potential , childbearing potential , must abstinent must use effective method birth control 30 day prior first vaccination must agree continue precaution two month completion vaccination series . Exclusion criterion : Pregnant breastfeeding ( woman must least three month postpregnancy breastfeed enter study ) . A woman plan become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution vaccination phase study , i.e . two month last vaccine dose ( Month 0 8 ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 84 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day ( i.e . day 0 29 ) first dose study vaccine . Planned administration/administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Previous administration component investigational vaccine Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . History HPV infection/treatment plan treatment evaluate abnormal cervical cytology ( Pap smear ) test , e.g . colposcopy . Any medically diagnose suspected immunodeficient condition base medical history physical examination . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . History chronic condition ( ) require treatment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine , plan administration study period . Enrolment defer subject outside specify window . Acute disease time enrolment . Heavy bleeding ( menstruation ) heavy vaginal discharge pelvic exam perform ( cervical sample take ) . Enrolment deferred condition resolve accord investigator medical judgement .</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Cervical Infection</keyword>
</DOC>